Backed by gi­ants, an­tibi­otics up­start Macrolide gets $20M and an ex-No­var­tis ex­ec as CEO

An an­tibi­otics start­up found­ed by the same guy who start­ed boom-and-bust an­tibi­otics com­pa­ny Tetraphase has hauled in $20 mil­lion in new cap­i­tal and a long­time No­var­tis ex­ec­u­tive as its new pres­i­dent and CEO.

Ma­hesh Karande

With cash in hand and a new chief at the helm, the com­pa­ny plans to tack­le some of the most dan­ger­ous su­per­bugs around by tweak­ing an old class of an­tibi­otics.

Wa­ter­town, MA-based Macrolide Phar­ma­ceu­ti­cals raised the Se­ries B round from three phar­ma gi­ants, in­clud­ing the ven­ture arms of Glax­o­SmithK­line (SR One), No­var­tis (No­var­tis Ven­ture Fund), and Roche (Roche Ven­tures), among oth­er in­vestors.

Macrolide al­so has a big phar­ma ex­ec­u­tive on board with the re­cruit­ment of Ma­hesh Karande, who spent sev­er­al years hop­ping around the world lead­ing No­var­tis’ in­ter­na­tion­al busi­ness units. He was a VP and on­col­o­gy busi­ness head in the US, pres­i­dent and phar­ma head for Africa and Egypt, and head of strat­e­gy and busi­ness de­vel­op­ment for Asia-Pa­cif­ic, Mid­dle East and Africa. But Karande left No­var­tis last year to join Intar­cia as VP and gen­er­al man­ag­er — a role he left to take the helm at Macrolide.

As its name sug­gests, Macrolide (the com­pa­ny) is fo­cused on macrolides, a class of an­tibi­otics that has been wide­ly used for decades to treat pneu­mo­nia and oth­er bac­te­r­i­al in­fec­tions. The ef­fec­tive­ness of these an­tibi­otics has been neg­a­tive­ly im­pact­ed by bac­te­ria’s frus­trat­ing abil­i­ty to be­come im­mune to drugs.

An­drew My­ers

But Macrolide says its found a way to en­gi­neer a so­lu­tion. The start­up was found­ed on tech from the lab of An­drew My­ers, a Har­vard Uni­ver­si­ty chemist. You might rec­og­nize My­ers as the guy who co-found­ed Tetraphase, an an­tibi­otics mak­er that grew to a pub­lic val­u­a­tion of over $1 bil­lion be­fore crash­ing hard fol­low­ing a Phase III flop of its lead an­tibi­ot­ic.

Macrolide has an ex­clu­sive li­cense from My­ers’ lab that gives the start­up ac­cess to tech­nol­o­gy to en­gi­neer syn­thet­ic macrolides from scratch. Macrolide says its tech can ex­pand the ther­a­peu­tic range of these drugs to in­clude not just gram-pos­i­tive in­fec­tions, but al­so gram-neg­a­tive ones — those dan­ger­ous in­fec­tions for which treat­ments are lim­it­ed.

The new fi­nanc­ing round is meant to sup­port work that will back up an IND ap­pli­ca­tion for its lead pro­gram for re­sis­tant gram-neg­a­tive pathogens.

“This po­si­tions Macrolide to fur­ther the pi­o­neer­ing work the team has done to date in ad­vanc­ing new macrolide an­tibi­otics with Gram-neg­a­tive ac­tiv­i­ty,” Karande said in a state­ment. “We be­lieve that ad­vanc­ing first-in-class an­tibi­otics that are ac­tive against lethal mul­ti-drug re­sis­tant bac­te­ria opens the door to a new and mean­ing­ful way to ad­dress the grow­ing pub­lic health is­sue of treat­ment gaps due to an­tibi­ot­ic re­sis­tance.”

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

AJ Patel was recovering from a complicated brain surgery when his oncologist burst into the hospital room yelling, “I’ve got some really great news for you!”

For two years, Patel had been going from doctor to doctor trying to diagnose his wheezing, only to be dealt the devastating news that he had stage IV lung cancer and only six months to live. And then they found the brain tumors.

“What are you talking about?” Patel asked. He had never seen an oncologist so happy.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Anthony Fauci (AP Images)

West Vir­ginia man faces prison time for threat­en­ing emails to Fau­ci, oth­er health of­fi­cials

NIAID director Anthony Fauci gained hero status amid the pandemic, earning Americans’ trust and even Time magazine’s Guardian of the Year title. But he and other federal health officials have also faced intense threats, according to charges brought by the US Department of Justice.

A West Virginia man is facing up to 10 years in prison after threatening Fauci, former NIH director Francis Collins, and HHS assistant secretary for health Rachel Levine via email, the DOJ said on Monday. Thomas Patrick Connally, Jr., pleaded guilty on Monday to using an anonymous email address to threaten the officials for performing their official duties, including discussing Covid-19 testing and prevention.

Mihael Polymeropoulos, Vanda Pharmaceuticals CEO

Phar­ma com­pa­ny con­tin­ues its FDA law­suit spree, this time af­ter agency de­nies fast-track des­ig­na­tion

Vanda Pharmaceuticals is making a name for itself, at least in terms of suing the FDA.

The DC-headquartered firm on Monday filed its latest suit against the agency, with the company raising concerns over the FDA’s failure to grant a fast track designation for Vanda’s potential chronic digestive disorder drug tradipitant, which is a neurokinin 1 receptor antagonist.

Specifically, Vanda said FDA’s “essential point” in its one-page denial letter on the designation pointed to “the lack of necessary safety data,” which was “inconsistent with the criteria for … Fast Track designation.”

Stéphane Bancel, Moderna CEO (Charles Krupa/AP Images)

Mod­er­na chief Ban­cel to do­nate about $355M worth of ear­ly stock to char­i­ty

Four days ago, Moderna CEO Stéphane Bancel was made a Chevalier — basically knighted — in his home country of France. And now the billionaire CEO said he will exercise and donate about  $355 million in stock options.

Bancel announced early Tuesday via a blog post that he and his wife Brenda will be donating the after-tax proceeds of his original stock options to charity — the stock options Bancel was granted back in 2013 after he became CEO, two years after he first joined the mRNA specialist outfit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Mod­er­na seeks to dis­miss Al­ny­lam suit over Covid-19 vac­cine com­po­nent, claim­ing wrong venue

RNAi therapeutics juggernaut Alnylam Pharmaceuticals made a splash in March when it sued and sought money from both Pfizer and Moderna regarding their use of Alnylam’s biodegradable lipids, which Alnylam claims have been integral to the way both companies’ mRNA-based Covid-19 vaccines work.

But now, Moderna lawyers are firing back, telling the same Delaware district court that Alnylam’s claims can only proceed against the US government in the Court of Federal Claims because of the way the company’s contract is set up with the US government. The US has spent almost $10 billion on Moderna’s Covid-19 vaccine so far.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

(Credit: Shutterstock)

Cracks in the fa­cade: Is phar­ma's pan­dem­ic ‘feel good fac­tor’ wan­ing?

The discordant effects of the Covid-19 pandemic on pharma reputation continues. While the overall industry still retains a respectable halo from its Covid-19 quick response and leadership, a new patient group study reveals a different story emerging in the details.

On one hand, US patient advocacy groups rated the industry higher-than-ever overall. More than two-thirds (67%) of groups gave the industry a thumbs up for 2021, a whopping 10 percentage point increase over the year before, according to the PatientView annual study, now in its 9th year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

David Sinclair, Genocea Biosciences co-founder (Alpha Wave Global)

Geno­cea reach­es end of road, delist­ing from Nas­daq and let­ting go of re­main­ing staff

A pivot into neoantigen immunotherapies was not enough to save Genocea Biosciences after all.

The 16-year-old biotech said it would be closing down and laying off all remaining employees “except those deemed necessary to complete an orderly wind down” of operations. It has also delivered a formal notice to Nasdaq, notifying the stock exchange of its intent to delist voluntarily.

The move comes a month after Genocea laid off 75% of its workforce and revealed it’s looking for strategic alternatives, such as a sale, merger or reverse merger. At the end of 2021, it had 74 employees.

Alan Wise (L) and Peter Trill (Duke Street Bio)

They sold their last biotech to Mer­ck. Now they're back with a PARP out­fit named af­ter a Lon­don street

In 2016, Peter Trill and Alan Wise sold IOmet Pharma (an I/O outfit as the name suggests) to Merck for $400 million.

Now, some six years later, the duo has returned with another cancer biotech, Duke Street Bio, that emerged from stealth Tuesday. Duke Street Bio, named for the street where it’s located in London, is making its public debut as a next-gen PARP player, hoping to break into a field that already has a number of Big Pharma competitors.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Michael Corbo, Pfizer CDO of inflammation & immunology

UP­DAT­ED: Plan­ning ahead for crowd­ed ul­cer­a­tive col­i­tis mar­ket, Pfiz­er spells out PhI­II da­ta on $6.7B Are­na drug

Pfizer has laid out the detailed results behind its boast that etrasimod — the S1P receptor modulator at the center of its $6.7 billion buyout of Arena Pharma — is the winner of the class, potentially leapfrogging an earlier entrant from Bristol Myers Squibb.

Pivotal data from the ELEVATE program in ulcerative colitis — which consists of two Phase III trials, one lasting 52 weeks and the other just 12 weeks — illustrate an “encouraging balance of efficacy and safety,” according to Michael Corbo, chief development officer of inflammation & immunology at Pfizer. The company is presenting the results as a late breaker at Digestive Disease Week.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.